KALA BIO Cuts Quarterly Net Loss ~90% to $0.8M, Ends Quarter With $7M Cash and No Debt
KALA sits 37% above its 52-week low of $0.115 on light trading volume (0.1× avg).
Summary
KALA BIO reported a preliminary third-quarter net loss of about $0.8 million, down from $7.6 million a year earlier — roughly a 90% reduction, per CEO Avi Minkowitz. The nine-month loss narrowed to about $4.0 million from $27.7 million. The company ended September 30 with roughly $7.0 million in cash, cash equivalents and short-term investments and no debt, a sharp improvement from the sub-$0.1 million cash position disclosed in the Q2 10-Q. That cash figure matters most here: the company has a Nasdaq delisting determination outstanding and shareholder authority for a reverse split of 1-for-2 up to 1-for-300 approved at the November 3 annual meeting. The numbers are unaudited and preliminary; the full 10-Q is expected on or about November 16, 2026.
At the time of this announcement, KALA was trading at $0.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.11 to $95.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: TMX Newsfile.